1. Introduction {#sec1-cancers-10-00213}
===============

More than 15% of human cancers are caused by infectious agents \[[@B1-cancers-10-00213]\]. Seven human viruses are associated with the majority of pathogen-related tumors, namely, the Epstein--Barr virus (EBV), hepatitis B (HBV) and C (HCV) viruses, human T cell lymphotropic virus 1 (HTLV-1), human papillomaviruses (HPV), Kaposi's sarcoma herpesvirus (HHV8), and Merkel cell polyomavirus (MCPyV) \[[@B2-cancers-10-00213]\]. Human oncoviruses, although have very different molecular characteristics, share similar features in the mechanisms of tumorigenesis, such as the ability to subvert the host cell signaling pathways involved in the regulation of cell proliferation, genomic stability, differentiation, apoptosis, and recognition by the immune system \[[@B3-cancers-10-00213]\]. In general, human oncoviruses are necessary but not sufficient for full cell transformation. In fact, many people become infected by one or more oncoviruses at some point in their lifetime but only a small fraction of infected subjects eventually develop cancer after decades of persistent infection and viral-related insults to the infected cells. During this long coexistence, multiple genetic and epigenetic alterations accumulate in the chronically infected cells, concurring to the multistage process of cancer development.

The oncogenic activity of tumor viruses mainly relies on their ability to interfere with the p53 signaling cascade in the infected cells \[[@B4-cancers-10-00213]\]. The impairment of oncosuppressors by viral factors was first identified by the study of large and small T antigens encoded by the simian vacuolating virus 40 (SV40) demonstrating their ability to inhibit the activity of tumor suppressors such as p53, pRb, p107, and p130/Rb and to cause evasion of apoptosis \[[@B5-cancers-10-00213]\]. Many in vitro and in vivo studies further corroborated the important aptitude of human viruses to deregulate the activity of p53 \[[@B6-cancers-10-00213],[@B7-cancers-10-00213],[@B8-cancers-10-00213]\]. This review describes several mechanisms used by the seven human oncoviruses to directly or indirectly inactivate p53 function.

2. The Tumor Suppressor p53 {#sec2-cancers-10-00213}
===========================

The p53 protein is a stress sensor regulating many cell pathways, such as cell cycle arrest, senescence, apoptosis, metabolic alterations, DNA repair, and other mechanisms of tumor suppression \[[@B9-cancers-10-00213]\]. Following a cell insult, p53 is rapidly phosphorylated at N-terminus sites by different kinases, including ATM, ATR, CHK1, CHK2, JNK, VRK1, PLK3, and CK1, and the activated protein becomes able to selectively regulate the transcription of more than 200 genes \[[@B10-cancers-10-00213],[@B11-cancers-10-00213],[@B12-cancers-10-00213]\]. Furthermore, the N-terminal-phosphorylated p53 binds to transcriptional coactivators, such as p300 or PCAF, which acetylate the residues at the C-terminus of p53, increasing its stability and binding affinity to the promoters of many genes \[[@B13-cancers-10-00213],[@B14-cancers-10-00213]\]. When the stress response is completed, p53 is reverted to its unphosphorylated form, and its levels are reported to the basal conditions by the activity of the MDM2 protein which ubiquitylates the C-terminal domain of p53 causing its proteasomal degradation \[[@B15-cancers-10-00213],[@B16-cancers-10-00213],[@B17-cancers-10-00213]\]. The interaction between p53 and MDM2 is inhibited by the phosphorylation of p53 at residues Ser15, Thr18, or Ser20 \[[@B18-cancers-10-00213]\].

In the majority of human cancers, p53 activity is often impaired by missense mutations distributed within the exons 4--8 in the *TP53* gene, encoding for the DNA-binding domain \[[@B19-cancers-10-00213]\]. In most cases, mutated p53 proteins become inactive but acquire stability and accumulate in cancer cells \[[@B20-cancers-10-00213]\]. Some mutant p53 proteins, besides losing their oncosuppressor activities, acquire oncogenic features (gain of functions) that endow the cells with overgrowth and survival advantages \[[@B21-cancers-10-00213]\].

The viral-associated tumors rarely harbor mutations in the oncosuppressor proteins. However, in such tumors, the oncogenic viruses interfere with p53 activity by different mechanisms, such as direct binding of viral oncoproteins to p53, phosphorylation of p53 by viral kinases, ubiquitylation, activation of MDM2 expression, which is a negative regulator of p53, or other indirect mechanisms \[[@B3-cancers-10-00213]\].

3. The Epstein--Barr Virus (EBV) {#sec3-cancers-10-00213}
================================

The EBV is a herpesvirus with a genome of 184 kb linear double-stranded DNA containing 70 open reading frames (ORFs) coding for latent and lytic proteins. EBV infection is associated with several human malignancies, including endemic Burkitt lymphoma and nasopharyngeal carcinoma \[[@B22-cancers-10-00213],[@B23-cancers-10-00213]\]. The EBV immediate-early transcription factor BZLF1 is the main regulator of the viral life cycle by controlling the switch between its latent and lytic stages \[[@B24-cancers-10-00213]\].

The BZLF1 protein directly interacts with p53 and acts as an adaptor for the elongin BC--cullin 5--SOCS box ubiquitin--protein ligase complex, causing the p53 degradation via a ubiquitin--proteasome pathway independently of MDM2 \[[@B25-cancers-10-00213]\] ([Figure 1](#cancers-10-00213-f001){ref-type="fig"}). Moreover, the viral lytic replication activates the DNA damage response, which causes C-terminus phosphorylation of p53 and further enhances its binding affinity to BZLF1 \[[@B25-cancers-10-00213],[@B26-cancers-10-00213]\].

The EBNA3C protein, produced during the latent phase of EBV life cycle, directly interacts with the C-terminus region of p53, preventing its binding to promoters and the transcription of target genes, and also binds to and stabilizes the p53 regulators ING4, ING5, MDM2, and Gemin3, which inhibit cell apoptosis \[[@B27-cancers-10-00213],[@B28-cancers-10-00213]\].

Following EBV infection, the viral protein EBNA-1 causes genomic instability and at the same time counteracts the DNA damage response (DDR) activation by direct binding to the p53 regulator USP7 and upregulates the survivin protein by inhibiting the downstream caspase activation \[[@B29-cancers-10-00213],[@B30-cancers-10-00213]\]. Interference with the apoptotic pathway is also exerted by two BCL-2 homologues encoded by EBV, namely, BHRF1 and BALF1. The BHRF1 protein has been shown to contribute to the inhibition of p53-dependent DDR signaling by blocking the pro-apoptotic PUMA factor \[[@B31-cancers-10-00213]\].

Moreover, the LMP1 viral protein, which is constitutively expressed in EBV latently infected nasopharyngeal cells, has been shown to promote the accumulation of p53 by two mechanisms: (1) suppression of K48-linked ubiquitination of p53 mediated by the E3 ligase MDM2; (2) induction of K63-linked ubiquitination of p53 through the interaction with tumor necrosis factor receptor-associated factor 2 (TRAF2), which causes p53 accumulation \[[@B32-cancers-10-00213]\].

The current evidence is that EBV deregulates apoptosis by interfering with p53 activity at multiple levels, but further studies are needed to uncover the mechanisms by which EBV causes the full transformation of infected cells.

4. The Hepatitis B Virus {#sec4-cancers-10-00213}
========================

The HBV is a small hepadnavirus with a 3.2 kb circular double-stranded DNA genome containing four partial overlapping ORFs encoding the reverse transcriptase/polymerase (Pol), the capsid protein (core antigen HBcAg), three envelope proteins (L, M, and S), and the transactivating protein x (HBx) \[[@B32-cancers-10-00213]\]. HBx is a 154-amino acid protein involved in HBV transcription and viral replication \[[@B33-cancers-10-00213]\].

Many studies have indicated a complex interplay between HBx and p53. HBx is able to physically interact with the C-terminus of p53 and to inhibit its activity by sequestering the oncosuppressors in the cytoplasm \[[@B34-cancers-10-00213]\]. On the other hand, increased levels of p53 have been reported to repress HBx oncogenicity by causing its degradation via overexpression of the negative p53 regulator MDM2 in hepatocellular carcinoma (HCC) \[[@B35-cancers-10-00213]\]. However, the mutated HBx protein exhibits an enhanced inhibitory effect on p53 expression and its downstream signaling compared to wild-type HBx \[[@B36-cancers-10-00213]\]. More recently, it has been reported that HBx causes the overexpression of the long non-coding RNA HUR1 (lnc-HUR1), which in turn interacts with p53 and inhibits the transcriptional regulation of p21 and Bax, thus promoting cell proliferation \[[@B37-cancers-10-00213]\].

Mutations in the *TP53* gene are very frequent in HBV-related HCC. In geographic regions with high prevalence of HBV infection and exposure to aflatoxin B1 (AFB1), the hepatocellular carcinoma DNA often contains a non-synonymous mutation at codon 249 (R249S) in the *TP53* gene \[[@B38-cancers-10-00213]\]. The R249S p53 mutant is able to bind efficiently the HBx and to promote hepatocyte transformation \[[@B39-cancers-10-00213]\].

5. The Human T Cell Lymphotropic Virus-1 (HTLV-1) {#sec5-cancers-10-00213}
=================================================

The HTLV-1 is a retrovirus with a genome of 8.5 kb made of linear, dimeric, single-stranded RNA-positive molecules, containing structural and enzymatic genes as well as overlapping regulatory and accessory genes \[[@B40-cancers-10-00213]\]. The HTLV-1 is recognized as the etiologic agent of adult T-cell leukemia (ALT) and of degenerative, neurological disorders such as tropical spastic paraparesis and HTLV-1-associated myelopathy \[[@B41-cancers-10-00213],[@B42-cancers-10-00213]\]. The two transactivating regulatory proteins Tax and Rex are essential for viral replication. Tax is considered the main oncogenic factor of HTLV-1 for its ability to promote cell cycle entry by CDK activation and to inhibit p53 via the phosphatase Wip1-mediated modulation of p300/CBP nuclear factors \[[@B43-cancers-10-00213]\]. Studies in small animals established that functional inactivation of p53 precedes NF-κB activation and that p53 dysfunction caused by Tax is a critical early event in the onset of Tax-associated leukemia \[[@B44-cancers-10-00213]\].

6. The Human Papillomavirus (HPV) {#sec6-cancers-10-00213}
=================================

The HPVs are a large and heterogeneous group of small DNA viruses containing 8 Kb circular double-stranded genomes and belong to the Papillomaviridae family. They display a distinct tropism for mucosal (alpha HPVs) or cutaneous (beta and gamma HPVs) squamous epithelia \[[@B45-cancers-10-00213]\].

A group of twelve mucosal HPVs, defined as high-risk viruses, are considered the necessary cause of almost all cervical carcinoma and of a significant fraction of other anogenital and oropharyngeal cancers \[[@B46-cancers-10-00213]\]. The oncogenic activity is mainly due to the ability of early proteins E6 and E7 to subvert the cell cycle control \[[@B47-cancers-10-00213],[@B48-cancers-10-00213]\]. The HPV E6 is a short polypeptide of approximately 150 amino acids consisting of two zinc finger domains which allow the interaction with cellular proteins containing the LXXLL motif \[[@B49-cancers-10-00213]\]. The E6 proteins encoded by high-risk HPVs, but not those of low-risk HPVs, contain a PDZ-binding domain at the C terminus able to bind and degrade cellular targets containing PDZ motifs \[[@B50-cancers-10-00213]\]. The E7 protein encoded by high-risk HPVs is a small protein of approximately 98 amino acids, sharing sequence similarities with the adenovirus E1A protein and SV40 LT antigens \[[@B51-cancers-10-00213]\].

The high-risk HPV E6 oncoproteins directly interact with p53 by forming a complex with the E6AP, a cellular E3 ubiquitin ligase, which causes the polyubiquitination and proteasome-mediated degradation of the p53 oncosuppressor \[[@B7-cancers-10-00213],[@B52-cancers-10-00213],[@B53-cancers-10-00213]\]. HPV E6 also promotes the destabilization of p53 by altering the activity of enzymes involved in the modification of p53. Indeed, acetylation of p53, which increases its stability, is required for the responses to DNA damage and for the activation of oncogene checkpoints ([Figure 2](#cancers-10-00213-f002){ref-type="fig"}). The acetylation of p53 at the C-terminus by p300/CBP causes an increase of p53 transcriptional activity leading to growth arrest and apoptosis \[[@B14-cancers-10-00213]\]. High-risk HPV E6 prevents p300-mediated transactivation of p53 through the binding of the histone acetyltransferase at multiple sites \[[@B54-cancers-10-00213]\] and causes the degradation of the histone acetyltransferase hADA3, which is also required for p53-mediated transcriptional activation and apoptosis \[[@B55-cancers-10-00213]\]. The phosphorylation of p53 mediated by ATR prevents its degradation by the MDM2 oncoprotein and activates the p53-dependent DNA repair machinery. However, HPV E6 is able to delay ATR activation with consequent degradation of p53 and abrogation of cell cycle arrest and DNA repair \[[@B56-cancers-10-00213]\]. In addition, HPV E6 has been shown to mask the nuclear localization signal of p53, causing its cytoplasmic retention and decrease of its nuclear transcriptional activity \[[@B57-cancers-10-00213]\].

Cutaneous beta HPVs are involved in skin carcinogenesis \[[@B58-cancers-10-00213]\]. The E6 proteins encoded by beta HPV 38 and HPV 92 have been shown to efficiently interact with p53, inducing its stabilization \[[@B59-cancers-10-00213]\]. Beta HPV 17 E6, despite its weak affinity for p53, is able to cause accumulation of p53 in the cells \[[@B59-cancers-10-00213]\]. An additional study showed that HPV 49 E6, similarly to the high-risk mucosal HPV E6, binds and promotes the degradation of p53 via the E6AP-dependent proteasome pathway \[[@B60-cancers-10-00213]\]. Moreover, the E6 proteins encoded by HPV 5 and HPV 8 interact with and cause p300 degradation via the proteasome pathway, which is activated by a decreased S1834 phosphorylation at the C-terminus of p53 \[[@B61-cancers-10-00213]\]. The interaction of cottontail rabbit papillomavirus (CRPV) E6 and HPV 38 E6 with the histone acetyltransferase p300 causes the block of p53-mediated apoptosis \[[@B62-cancers-10-00213]\]. In fact, the E6 mutants which are unable to bind p300 do not inhibit p53 acetylation, p53-dependent transcription, and apoptosis \[[@B62-cancers-10-00213]\].

The E7 proteins encoded by high-risk HPVs are capable of deregulating p53-mediated cell cycle arrest by interfering with the cyclin-dependent kinase inhibitor p21 (CDKN1A), which represents a key mediator of p53 checkpoint control \[[@B63-cancers-10-00213],[@B64-cancers-10-00213],[@B65-cancers-10-00213]\]. The HPV E7 oncoprotein has also been shown to disrupt the pRB-related transcriptional repressor complex DREAM (DP, RB-like, E2F4, and MuvB), which is an important effector of cell cycle checkpoint activation mediated by the p53--p21--DREAM pathway \[[@B66-cancers-10-00213],[@B67-cancers-10-00213]\]). The disruption of such complex by E7 abrogates p53-dependent downregulation of DREAM, causing increased expression of a large number of cell cycle genes and impairment of cell cycle checkpoints \[[@B68-cancers-10-00213],[@B69-cancers-10-00213]\].

7. The Hepatitis C Virus {#sec7-cancers-10-00213}
========================

The HCV of the flaviviridae family has a single-stranded RNA genome encoding a 3000-amino acid polyprotein which is cleaved by viral and cellular proteases into four structural proteins, named capsid protein C, envelope glycoproteins E1 and E2, and protein P7, and in six nonstructural proteins, named NS2, NS3, NS4A, NS4B, NS5A, and NS5B, \[[@B70-cancers-10-00213]\]. HCV is the cause of hepatocellular carcinoma and lymphoproliferative disorders.

The core protein of HCV directly binds the C-terminus of p53 causing the increase of p53 transcriptional activity and elevated expression of p21 (CDKN1A), a major target of p53 \[[@B71-cancers-10-00213]\]. In addition, the core protein interacts also with hTAF(II), a component of the transcriptional factor complex and coactivator of p53, suggesting that it widely modulates promoter activities during HCV infection \[[@B71-cancers-10-00213]\].

HCV NS2 has been shown to interfere with the DNA damage checkpoint pathway by causing retention of p53 in the cytoplasm and favoring cell proliferation \[[@B72-cancers-10-00213]\].

HCV NS5A has been shown to bind directly to p53 and hTAF(II), to partially sequester them in the cytoplasm, and to suppress p53-mediated transcriptional transactivation and apoptosis during HCV infection \[[@B73-cancers-10-00213]\]. Further studies by microarray analysis showed that HCV NS5A causes the downregulation of nine genes, including *TP53*, and the upregulation of 10 genes, including those coding for survivin, NOS2A, cyclin D1, and NF-κB, which are all associated with signal transduction \[[@B73-cancers-10-00213]\]. The inhibition of p53 by HCV NS5A has also been shown to interfere with the DNA damage checkpoint pathway by causing the downregulation of the growth arrest and DNA-damage-inducible gene 45-α (GADD45α) \[[@B74-cancers-10-00213]\]. The use of pharmacological inhibitors or small interfering RNAs can reverse NS5A-mediated downregulation of p53 and GADD45α, suggesting that NS5A is a main contributor to liver carcinogenesis \[[@B74-cancers-10-00213]\].

8. The Kaposi's Sarcoma Herpesvirus (HHV8) {#sec8-cancers-10-00213}
==========================================

The HHV8 is a human gamma herpesvirus with a linear double-strand DNA genome of approximately 165 kb containing 100 ORFs. The virus has a sequence homology to the closely related EBV and unique genes not similar to any other herpesvirus \[[@B75-cancers-10-00213]\]. The HHV8 is recognized as the causative agent of three different types of malignancies, i.e., Kaposi's sarcoma (KS), multicentric Castelman's disease, and a form of AIDS-related primary effusion lymphoma (PEL) \[[@B76-cancers-10-00213],[@B77-cancers-10-00213]\].

Nearly 25 unique genes may represent captured and diverged homologues of cellular genes that are referred to as ORF-K. A number of proteins encoded by conserved or unique genes have been suggested to be responsible for KS pathogenesis: K1, K2, vMIPS, K4, K4.1, K5, K9, K12, ORF-6, ORF-71, ORF-72, ORF-73, ORF-74, and K15 \[[@B78-cancers-10-00213]\]. Among these, LANA and v-cyclin, encoded by ORF-72 and ORF-73, respectively, have demonstrated to affect cell cycle checkpoint mediators. The LANA protein acts as an adaptor molecule for an E3 ubiquitin complex via a specific protein motif and causes ubiquitylation and degradation of p53 \[[@B79-cancers-10-00213]\]. LANA inhibits both p53 and pRB tumor suppressor pathways, allowing the infected cells to become resistant to anti-growth signals and cell cycle arrest and to accumulate genetic damages \[[@B80-cancers-10-00213],[@B81-cancers-10-00213]\].

ORF K9 codes for a viral homolog of interferon inducible factor vIRF-1, which inhibits the tumor suppressor p53 via the interaction with its co-activator p300/CBP and promotes its ubiquitination and delocalization to the cytoplasm \[[@B82-cancers-10-00213]\]. In addition, vIRF-1 can prevent apoptosis during viral replication by direct inhibition of pro-apoptotic BH3 domain-containing proteins such as BIM \[[@B83-cancers-10-00213]\]. The protein vIRF-1 is also able to inhibit the activation of p53 by ATM, causing suppression of apoptosis induced by DNA damage \[[@B84-cancers-10-00213]\]. The virus-encoded viral interferon regulatory factor 3 (vIRF-3) gene is a latent gene which is involved in the regulation of apoptosis, cell cycle, antiviral immunity, and tumorigenesis. In addition, vIRF-3 has been shown to interact with the DNA-binding domain of p53, to inhibit p53 phosphorylation on serine residues S15 and S20, and to destabilize the oncosuppressor by increasing its polyubiquitination and proteasome-mediated degradation \[[@B85-cancers-10-00213]\].

The K-bZIP protein encoded by ORF K8 has a basic region--leucine zipper and interacts with the DNA-binding region of p53, causing inhibition of p53-dependent transcription \[[@B86-cancers-10-00213]\]. Other viral proteins, such as the lytic protein vIRF4, lack E3 ligase activity but they are capable of forming multi-protein complexes with ubiquitin ligase activity and facilitate the proteasome-mediated degradation of p53 \[[@B65-cancers-10-00213]\]. Thus, HHV8 has several efficient mechanisms to downregulate p53 function and facilitate uncontrolled cell proliferation and tumor growth ([Figure 3](#cancers-10-00213-f003){ref-type="fig"}).

9. The Merkel Cell Polyomavirus (MCPyV) {#sec9-cancers-10-00213}
=======================================

The MCPyV is a polyomavirus with a double-stranded circular DNA genome of 5.4 kb. The virus codes for three early viral transcripts, namely, the large T antigen (LT), small T antigen (sT), and 57KT, which are produced by alternative splicing of T early region, and for two structural capsid proteins (VP1 and VP2) which are coded by the late region of the viral genome \[[@B87-cancers-10-00213]\]. The virus is associated with the development of Merkel cell carcinoma (MCC) which is the most aggressive skin cancer in humans \[[@B88-cancers-10-00213]\].

The MCPyV LT has shown to play a key role in the viral life cycle as well as in carcinogenesis \[[@B89-cancers-10-00213],[@B90-cancers-10-00213]\]. The full-length MCPyV LT protein does not bind directly p53 but causes a reduction of p53-dependent transcription in reporter assays \[[@B91-cancers-10-00213]\]. The truncated LT protein, expressed in the majority of MCPyV-related tumours, does not bind to p53 or reduce p53-dependent transcription but shows very high binding affinity for Rb and is able to partially relocalize Rb to the cytoplasm \[[@B91-cancers-10-00213]\].

10. Targeting the p53 Proteasome in Virus-Related Human Cancers {#sec10-cancers-10-00213}
===============================================================

The levels of p53 are tightly controlled by the cellular antagonist MDM2 which regulates the stability and activity of p53 by an E3-ubiquitin ligase activity \[[@B92-cancers-10-00213]\]. The crystal structure of p53 in complex with MDM2 and MDMX revealed that only three p53 amino acid residues (Phe19, Trp23, and Leu26) contribute extensively to the physical interaction between p53 and MDM2/MDMX proteins \[[@B93-cancers-10-00213]\].

A variety of compounds able to bind the N-terminal pocket of MDM2 and to disrupt the MDM2--p53 interaction have been developed and offer new therapeutic opportunities for tumors harboring wild-type p53 \[[@B94-cancers-10-00213]\]. The most promising results have been obtained with the use of Nutlin-3, a small cis-imidazoline analogue competing with MDM2 for binding to p53 \[[@B95-cancers-10-00213]\]. Several in vitro and in vivo studies have demonstrated that Nutlin-3 is able to selectively enhance apoptosis in cancer cells containing wild-type p53 \[[@B96-cancers-10-00213]\]. Nutlin-3 is non-genotoxic and protects normal cells from mitotic toxicity \[[@B96-cancers-10-00213]\]. Moreover, Nutlin-3 can activate the p53 pathway and sensitize EBV-positive nasopharyngeal carcinoma cells to cisplatin-induced apoptosis \[[@B97-cancers-10-00213]\] The use of Nutlin-3 in Burkitt lymphoma cells chronically infected with EBV has been shown to disrupt the interaction of p53 with MDM2 and to facilitate apoptosis \[[@B98-cancers-10-00213]\]. Similar results have been observed by treating EBV-positive lymphoblastoid cells with Nutlin-3, which caused p53 reactivation and apoptosis \[[@B99-cancers-10-00213]\].

In addition, the restoration of the p53 pathway with Nutlin-3 has been shown to cause a specific and highly potent activation of cell death in HHV8-related pleural effusion lymphomas \[[@B100-cancers-10-00213]\]. Such results demonstrated that Nutlin-3 is able to disrupt the p53--MDM2--LANA complex and to suppress the anti-apoptotic activity caused by the complex created by LANA, p53, and MDM2 \[[@B100-cancers-10-00213],[@B101-cancers-10-00213],[@B102-cancers-10-00213]\].

Similarly to Nutilin-3, several other small molecule inhibitors able to bind MDM2 and to inhibit its association with p53 have been developed and evaluated in preclinical and clinical studies \[[@B103-cancers-10-00213]\]. Such therapeutic compounds include cis-imidazoline (NCT00559533, NCT01635296, NCT01605526, NCT01462175, NCT01773408), spiro-oxindole (NCT01636479, NCT01985191), imidazothiazole (NCT01877382), dihydroisoquinolinone (NCT01760525), piperidines (NCT01451437), piperidinone (NCT01723020, NCT02110355) and pyrrolidine (NCT02407080) molecules which are in phase I clinical trials for the treatment of several solid tumors \[[@B103-cancers-10-00213]\].

Different inhibitors targeting the p53--MDM2 interaction, based on phage display peptide libraries \[[@B104-cancers-10-00213]\] or on the designed sequences of stapled peptides derived from the α-helix of the p53 transactivation domain \[[@B105-cancers-10-00213]\], have been developed. Indeed, the restoration of p53 activity has been achieved by targeting MDMX with the stapled peptide SAH-p53-8, which blocks the formation of the p53--MDMX complex and restores the transcriptional upregulation of p53-related genes and the reduction of tumor cell viability \[[@B106-cancers-10-00213]\]. The dual inhibition of MDM2/MDMX with the stapled α-helical peptide ALRN-6924 (Aileron Therapeutics, Cambridge, MA, USA) has been demonstrated to strongly activate p53-dependent transcription and to produce a marked antileukemic effect \[[@B107-cancers-10-00213]\]. Moreover, ALRN-6924 showed promising pre-clinical activity in cell lines harboring wild-type p53 and in patient-derived xenograft models, as well as induced complete remission in a patient with an angioimmunoblastic T-cell lymphoma containing wild-type p53 \[[@B108-cancers-10-00213]\]. This compound has recently entered phase I clinical testing (NCT02264613).

In HPV-related cancers, E6-mediated degradation of p53 represents an important mechanism of cell transformation \[[@B109-cancers-10-00213]\]. The E6 proteins of high-risk HPVs interact with the LxxLL motif of the cellular ubiquitin ligase E6AP, which leads to the recruitment and polyubiquitination of p53 \[[@B110-cancers-10-00213]\]. The x-ray structure of the HPV16 E6--E6AP complex showed a distinct binding pocket for E6AP in the E6 protein. This pocket provides a docking site for peptide inhibitors such as pep11\*\* which binds to HPV16 E6 and induces apoptosis of HPV16-positive cancer cells \[[@B111-cancers-10-00213]\]. The binding of pep11\*\* blocks E6-mediated p53 degradation by capturing E6 in trimeric E6--pep11\*\*--p53 complexes \[[@B112-cancers-10-00213]\].

In addition, the binding of the E6AP LxxLL-derived peptide to the E6 oncoprotein renders the conformation of E6 competent for interaction with p53 and causes the formation of a p53-binding cleft on the E6 \[[@B7-cancers-10-00213]\]. The p53-binding site on E6 may represent a second potential binding site for peptide inhibitors to be used in combination strategies targeting both the LxxLL pocket and the p53-binding cleft on E6 to obtain an efficient disruption of the E6--E6AP--p53 complex \[[@B7-cancers-10-00213]\].

The further development of specific molecules targeting the interaction of p53 with viral oncoproteins might provide promising strategies to interfere with virus-related tumorigenesis.

11. Conclusions {#sec11-cancers-10-00213}
===============

The development of virus-associated cancer depends on the complex interplay between host and viral factors. The seven recognized human oncoviruses encode regulatory proteins that subvert cell signaling and modulate growth and differentiation. The functional impairment of p53 activity is a crucial mechanism of viral-related carcinogenesis. Several viral proteins have been shown to interact directly or indirectly with p53, facilitating MDM2/MDMX-mediated degradation. The study of the crystallographic structure of p53 and of its interactions with HPV E6 and cellular proteins has provided the basis for the development of specific inhibitors of p53 degradation. Several pharmaceutical companies have developed drugs targeting the negative regulators of p53, such as MDM2 and MDMX, that are in preclinical study and into early-phase clinical trials. Further studies are needed to establish whether similar structural propensities exist within other viral proteins that interact with p53 and its regulators.
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